[go: up one dir, main page]

WO2002097035A3 - Proteines secretees - Google Patents

Proteines secretees Download PDF

Info

Publication number
WO2002097035A3
WO2002097035A3 PCT/US2002/016234 US0216234W WO02097035A3 WO 2002097035 A3 WO2002097035 A3 WO 2002097035A3 US 0216234 W US0216234 W US 0216234W WO 02097035 A3 WO02097035 A3 WO 02097035A3
Authority
WO
WIPO (PCT)
Prior art keywords
secp
secreted proteins
polynucleotides
agonists
diagnosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/016234
Other languages
English (en)
Other versions
WO2002097035A2 (fr
Inventor
Henry Yue
Ernestine A Lee
Shanya D Becha
Mariah R Baughn
Monique G Yao
Y Tom Tang
Janice K Au-Young
Preeti G Lal
Bridget A Warren
Brendan M Duggan
Uyen K Tran
Yuming Xu
Kavitha Thangavelu
Thomas W Richardson
Olga Bandman
Karen Anne Jones
Junming Yang
Brooke M Emerling
Anita Swarnakar
Wen Luo
Narinder K Chawla
Yalda Azimzai
Farrah A Khan
Dyung Aina M Lu
Jennifer A Griffin
Soo Yeun Lee
Neil Burford
Vicki S Elliott
Cynthia D Honchell
Ann He
Patricia M Mason
Joana X Li
April J A Hafalia
Rajagopal Gururajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to JP2003500204A priority Critical patent/JP2005507239A/ja
Priority to CA002448146A priority patent/CA2448146A1/fr
Priority to AU2002303843A priority patent/AU2002303843A1/en
Priority to US10/479,284 priority patent/US20040158039A1/en
Priority to EP02731905A priority patent/EP1578899A2/fr
Publication of WO2002097035A2 publication Critical patent/WO2002097035A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002097035A3 publication Critical patent/WO2002097035A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des protéines sécrétées humaines (SECP) et des polynucléotides qui identifient et qui sont codants pour SECP. Cette invention concerne aussi des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes. Cette invention concerne enfin des techniques de diagnostic, de traitement ou de prévention de pathologies associées à l'expression aberrante de SECP.
PCT/US2002/016234 2001-05-25 2002-05-21 Proteines secretees Ceased WO2002097035A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003500204A JP2005507239A (ja) 2001-05-25 2002-05-21 分泌タンパク質
CA002448146A CA2448146A1 (fr) 2001-05-25 2002-05-21 Proteines secretees
AU2002303843A AU2002303843A1 (en) 2001-05-25 2002-05-21 Secreted proteins
US10/479,284 US20040158039A1 (en) 2002-05-21 2002-05-21 Secreted proteins
EP02731905A EP1578899A2 (fr) 2001-05-25 2002-05-21 Proteines secretees

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US29372801P 2001-05-25 2001-05-25
US60/293,728 2001-05-25
US29701901P 2001-06-08 2001-06-08
US60/297,019 2001-06-08
US29929701P 2001-06-19 2001-06-19
US60/299,297 2001-06-19
US30053701P 2001-06-22 2001-06-22
US60/300,537 2001-06-22
US30193601P 2001-06-29 2001-06-29
US60/301,936 2001-06-29
US36243902P 2002-03-06 2002-03-06
US60/362,439 2002-03-06
US36364902P 2002-03-08 2002-03-08
US60/363,649 2002-03-08
US36604102P 2002-03-19 2002-03-19
US60/366,041 2002-03-19

Publications (2)

Publication Number Publication Date
WO2002097035A2 WO2002097035A2 (fr) 2002-12-05
WO2002097035A3 true WO2002097035A3 (fr) 2007-08-23

Family

ID=27575351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016234 Ceased WO2002097035A2 (fr) 2001-05-25 2002-05-21 Proteines secretees

Country Status (4)

Country Link
EP (1) EP1578899A2 (fr)
JP (1) JP2005507239A (fr)
CA (1) CA2448146A1 (fr)
WO (1) WO2002097035A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005093083A1 (ja) * 2004-03-29 2008-02-14 和久 前田 疾病予測方法、及びその利用方法
AU2013206613B2 (en) * 2005-09-12 2017-03-02 Biontech Ag Identification of tumor-associated antigens for diagnosis and therapy
EP1762575A1 (fr) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518055B2 (en) * 2001-03-26 2003-02-11 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518055B2 (en) * 2001-03-26 2003-02-11 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof

Also Published As

Publication number Publication date
EP1578899A2 (fr) 2005-09-28
CA2448146A1 (fr) 2002-12-05
AU2002303843A8 (en) 2007-09-20
WO2002097035A2 (fr) 2002-12-05
JP2005507239A (ja) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2001098468A3 (fr) Proteases
WO2003052075A3 (fr) Enzymes
WO2002038602A3 (fr) Proteines secretees
WO2003027228A3 (fr) Recepteurs et proteines associees a une membrane
WO2001098353A3 (fr) Proteines secretees
WO2002008396A3 (fr) Proteases
WO2002048337A3 (fr) Proteines secretees
WO2003029437A3 (fr) Proteines secretees
WO2003048305A3 (fr) Recepteurs et proteines associees aux membranes
WO2001079291A3 (fr) Proteines secretees
WO2002072794A3 (fr) Proteines de la superfamille des immunoglobulines
WO2003004615A3 (fr) Proteines secretees
WO2003042357A3 (fr) Enzymes
WO2002097060A3 (fr) Proteines associees aux carbohydrates
WO2002038744A3 (fr) Protéases
WO2002086069A3 (fr) Proteines secretees
WO2002070669A3 (fr) Proteines secretees
WO2003068943A3 (fr) Proteines secretees
WO2001071004A3 (fr) Proteases
WO2002026982A3 (fr) Proteines secretees
WO2003087300A3 (fr) Proteines secretees
WO2003025130A3 (fr) Recepteurs et proteines associees a la membrane
WO2002020736A3 (fr) Proteases
WO2003016506A3 (fr) Proteines secretees
WO2002066646A3 (fr) Proteines associees a la neurotransmission

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10479284

Country of ref document: US

Ref document number: 2448146

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003500204

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002731905

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002731905

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002731905

Country of ref document: EP